Therapeutic Variables in Cataract Surgery

This study has been completed.

First Received on November 30, 2006. Last Updated on August 17, 2007 History of Changes

Sponsor:	Innovative Medical
Information provided by:	Innovative Medical
ClinicalTrials.gov Identifier:	NCT00407017

Purpose

The purpose of this study is to compare patient outcomes in following cataract surgery in patients randomized to one of two surgical kits.

Condition	Intervention	Phase
Cataract Surgery	Drug: Gatifloxacin Drug: Ketorolac LS Drug: Pred Forte Drug: Moxifloxacin Drug: Nepafenac Drug: EconoPred Plus	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind

Resource links provided by NLM:

Further study details as provided by Innovative Medical:

Eligibility

Genders Eligible for Study:

Both

Criteria

Inclusion Criteria:

Males or females scheduled to undergo cataract surgery
Patients can be receiving monofocal IOLs only
Likely to complete all study visits and able to provide informed consent
Visual potential of 20/25 or better

Exclusion Criteria:

Known contraindications to any study medication or ingredients
Active ocular diseases or uncontrolled systemic disease
Active ocular allergies

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00407017

Locations

United States, Florida
The Center for Excellence in Eye Care
Miami, Florida, United States, 33176

Sponsors and Collaborators

Innovative Medical

Investigators

Principal Investigator:

William Trattler, MD

The Center For Excellence in Eye Care

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00407017 History of Changes
Other Study ID Numbers:	5264-T
Study First Received:	November 30, 2006
Last Updated:	August 17, 2007
Health Authority:	United States: Institutional Review Board

Additional relevant MeSH terms:

Cataract
Lens Diseases
Eye Diseases
Methylprednisolone acetate
Prednisolone acetate
Methylprednisolone
Methylprednisolone Hemisuccinate
Prednisolone
Ketorolac
Prednisolone phosphate
Gatifloxacin
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Anti-Inflammatory Agents
Therapeutic Uses

Pharmacologic Actions
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents
Gastrointestinal Agents
Neuroprotective Agents
Protective Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anti-Inflammatory Agents, Non-Steroidal

ClinicalTrials.gov processed this record on February 09, 2012